Based on this, we confirmed once again in clinical samples that the RORα/ECM1/VEGFR2 signaling axis is closely associated with PARP inhibitor resistance, disease progression, and survival prognosis in ovarian cancer. The gene discussed is ECM1; the disease is ovarian cancer.